Inflammation-induced IL-6 functions as a natural brake on macrophages and limits GN

Journal of the American Society of Nephrology

Volumn 26, Issue 7, 2015, Pages 1597-1607

  Luig, Michael ^a   Kluger, Malte A ^a   Goerke, Boeren ^a   Meyer, Matthias ^a   Nosko, Anna ^a   Yan, Isabell ^a   Scheller, Jürgen ^b   Mittrücker, Hans Willi ^a   Rose John, Stefan ^c   Stahl, Rolf A K ^a   Panzer, Ulf ^a   Steinmetz, Oliver M ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Department of Orthopedic Surgery   (Germany)

^c UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GLYCOPROTEIN GP 130; INTERLEUKIN 17; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN 6 RECEPTOR ALPHA; KI 67 ANTIGEN; MANNOSE RECEPTOR;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; FLUORESCENCE ACTIVATED CELL SORTING; HUMORAL IMMUNITY; IMMUNE COMPLEX NEPHRITIS; IN VITRO STUDY; INFLAMMATION; LEUKOCYTE; LIVER CELL; LUPUS ERYTHEMATOSUS NEPHRITIS; MACROPHAGE; MACROPHAGE ACTIVATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; SIGNAL TRANSDUCTION; SPLEEN CELL; ANALYSIS OF VARIANCE; ANIMAL; C57BL MOUSE; CELL CULTURE; CYTOLOGY; DISEASE MODEL; FLOW CYTOMETRY; GLOMERULONEPHRITIS; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROCEDURES; RANDOMIZATION; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

ANALYSIS OF VARIANCE; ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; GLOMERULONEPHRITIS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-6; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RANDOM ALLOCATION; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, INTERLEUKIN-6; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION;

EID: 84924580495     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2014060620     Document Type: Article

References (62)

1. Neurath MF, Finotto S: IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer. Cytokine Growth Factor Rev 22: 83-89, 2011
2. Kishimoto T: Interleukin-6: Frombasic science to medicine-40 years in immunology. Annu Rev Immunol 23: 1-21, 2005
3. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S: The pro-and antiinflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta 1813: 878-888, 2011
4. Taga T, Kishimoto T: Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol 15: 797-819, 1997
5. Rose-John S, NeurathMF: IL-6 trans-signaling: The heat is on. Immunity 20: 2-4, 2004
6. Rose-John S, Scheller J, Elson G, Jones SA: Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: Role in inflammation and cancer. J Leukoc Biol 80: 227-236, 2006
7. Jones SA, Scheller J, Rose-John S: Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest 121: 3375-3383, 2011
8. Hirano T, Yasukawa K, Harada H, Taga T, Watanabe Y, Matsuda T, Kashiwamura S, Nakajima K, Koyama K, Iwamatsu A, Tsunasawa S, Sakiyama F, Matsui H, Takahara Y, Taniguchi T, Kishimoto T: Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 324: 73-76, 1986
9. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK: Reciprocal developmental pathways for the generation of pathogenic effectorTH17andregulatoryTcells.Nature 441: 235-238, 2006
10. Zhou L, Ivanov II, Spolski R, Min R, Shenderov K, Egawa T, Levy DE, Leonard WJ, Littman DR: IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 8: 967-974, 2007
11. Mangan PR, Harrington LE, O'Quinn DB, HelmsWS, Bullard DC, Elson CO,Hatton RD,Wahl SM, Schoeb TR,WeaverCT: Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 441: 231-234, 2006
12. VeldhoenM, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B: TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24: 179-189, 2006
13. Serada S, FujimotoM,MiharaM, KoikeN,Ohsugi Y, Nomura S, Yoshida H, Nishikawa T, Terabe F,Ohkawara T, Takahashi T, Ripley B, Kimura A, Kishimoto T, Naka T: IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 105: 9041-9046, 2008
14. Yamamoto M, Yoshizaki K, Kishimoto T, Ito H: IL-6 is required for the development of Th1 cell-mediated murine colitis. J Immunol 164: 4878-4882, 2000
15. Fujimoto M, Serada S, Mihara M, Uchiyama Y, Yoshida H, Koike N, Ohsugi Y, Nishikawa T, Ripley B, Kimura A, Kishimoto T, Naka T: Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses. Arthritis Rheum 58: 3710-3719, 2008
16. Tanaka T, Narazaki M, Kishimoto T: Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases. FEBS Lett 585: 3699-3709, 2011
17. Schoels MM, van der Heijde D, Breedveld FC, Burmester GR, Dougados M, Emery P, Ferraccioli G, Gabay C, Gibofsky A, Gomez-Reino JJ, Jones G, Kvien TK, Murakami M, Nishimoto N, Smolen JS: Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: Systematic literature review and meta-analysis informing a consensus statement. Ann Rheum Dis 72: 583-589, 2013
18. Tanaka T, Narazaki M, Ogata A, Kishimoto T: A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy. Semin Immunol 26: 88-96, 2014
19. Aderka D, Le JM, Vilcek J: IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice. J Immunol 143: 3517-3523, 1989
20. Ulich TR, Yin S, Guo K, Yi ES, Remick D, del Castillo J: Intratracheal injection of endotoxin and cytokines. II. Interleukin-6 and transforming growth factor beta inhibit acute inflammation. Am J Pathol 138: 1097-1101, 1991
21. Ulich TR, Guo KZ, Remick D, del Castillo J, Yin SM: Endotoxin-induced cytokine gene expression in vivo. III. IL-6 mRNA and serum protein expression and the in vivo hematologic effects of IL-6. J Immunol 146: 2316-2323, 1991
22. Xing Z, Gauldie J, Cox G, Baumann H, Jordana M, Lei XF, Achong MK: IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest 101: 311-320, 1998
23. Riedy MC, Stewart CC: Inhibitory role of interleukin-6 in macrophage proliferation. J Leukoc Biol 52: 125-127, 1992
24. Tilg H, Trehu E, Atkins MB, Dinarello CA,Mier JW: Interleukin-6 (IL-6) as an anti-inflammatory cytokine: Induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 83: 113-118, 1994
25. Clutterbuck R, Powles R, Millar J, Catovsky D: Interleukin-6 and other gp130-dependent cytokines selectively inhibit proliferation of macrophagelineage hemopoietic progenitor cells. Exp Hematol 28: 1120-1128, 2000
26. Park SJ, Nakagawa T, Kitamura H, Atsumi T, Kamon H, Sawa S, Kamimura D, Ueda N, Iwakura Y, Ishihara K,MurakamiM, Hirano T: IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation. J Immunol 173: 3844-3854, 2004
27. Wendling D, Paccou J, Berthelot JM, Flipo RM, Guillaume-Czitrom S, Prati C, Dernis E, Direz G, Ferrazzi V, Ristori JM; CRI: New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases. Semin Arthritis Rheum 41: 503-510, 2011
28. Wendling D, Letho-Gyselinck H, Guillot X, Prati C: Psoriasis onset with tocilizumab treatment for rheumatoid arthritis. J Rheumatol 39: 657, 2012
29. Matsuo Y, Mizoguchi F, Kohsaka H, Ito E, Eishi Y, Miyasaka N: Tocilizumabinduced immune complex glomerulonephritis in a patient with rheumatoid arthritis. Rheumatology (Oxford) 52: 1341-1343, 2013
30. Kiberd BA: Interleukin-6 receptor blockage ameliorates murine lupus nephritis. J Am Soc Nephrol 4: 58-61, 1993
31. Cash H, Relle M, Menke J, Brochhausen C, Jones SA, Topley N, Galle PR, Schwarting A: Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: The IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus. J Rheumatol 37: 60-70, 2010
32. Ryffel B, Car BD, Gunn H, Roman D, Hiestand P, Mihatsch MJ: Interleukin-6 exacerbates glomerulonephritis in (NZB x NZW)F1 mice.AmJ Pathol 144: 927-937, 1994
33. Mihara M, Takagi N, Takeda Y, Ohsugi Y: IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/WF1 mice. Clin Exp Immunol 112: 397-402, 1998
34. Liang B,Gardner DB,Griswold DE, Bugelski PJ, Song XY: Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus. Immunology 119: 296-305, 2006
35. Karkar AM, Smith J, Tam FW, Pusey CD, Rees AJ: Abrogation of glomerular injury in nephrotoxic nephritis by continuous infusion of interleukin-6. Kidney Int 52: 1313-1320, 1997
36. Karkar AM, Tam FW, Proudfoot AE, Meager A, Rees AJ: Modulation of antibody-mediated glomerular injury in vivo by interleukin-6. Kidney Int 44: 967-973, 1993
37. Li S, Holdsworth SR, Tipping PG: Antibody independent crescentic glomerulonephritis inmuchaindeficient mice. Kidney Int 51:672-678, 1997
38. Tipping PG, Huang XR, Qi M, Van GY, Tang WW: Crescentic glomerulonephritis in CD4-and CD8-deficient mice. Requirement for CD4 but not CD8 cells. Am J Pathol 152: 1541-1548, 1998
39. Tipping PG, Holdsworth SR: T cells in glomerulonephritis. Springer Semin Immunopathol 24: 377-393, 2003
40. Turner JE, Paust HJ, Steinmetz OM, Panzer U: The Th17 immune response in renal inflammation. Kidney Int 77: 1070-1075, 2010
41. Steinmetz OM, Summers SA, Gan PY, Semple T, Holdsworth SR, Kitching AR: The Th17-defining transcription factor RORgt promotes glomerulonephritis. J Am Soc Nephrol 22: 472-483, 2011
42. Holdsworth SR, Tipping PG: Leukocytes in glomerular injury. Semin Immunopathol 29: 355-374, 2007
43. Nechemia-Arbely Y, Barkan D, Pizov G, Shriki A, Rose-John S, Galun E, Axelrod JH: IL-6/IL-6R axis plays a critical role in acute kidney injury. J Am Soc Nephrol 19: 1106-1115, 2008
44. Esposito P, BallettaMM, Procino A, Postiglione L,Memoli B: Interleukin-6 release fromperipheralmononuclear cells is associated to disease activity and treatment response in patients with lupus nephritis. Lupus 18: 1329-1330, 2009
45. Iijima T, Suwabe T, Sumida K, Hayami N, Hiramatsu R, Hasegawa E, Yamanouchi M, Hoshino J, Sawa N, Takaichi K, Oohashi K, Fujii T, Ubara Y: Tocilizumab improves systemic rheumatoid vasculitis with necrotizing crescentic glomerulonephritis [published online ahead of print February 18, 2014]. Mod Rheumatol doi:10.3109/ 14397595.2013.874748
46. Sumida K, Ubara Y, Suwabe T, Hayami N, Hiramatsu R, Hasegawa E, Yamanouchi M, Hoshino J, Sawa N, Takemoto F, Takaichi K, Ohashi K: Complete remission of myeloperoxidase-anti-neutrophil cytoplasmic antibody-associated crescentic glomerulonephritis complicated with rheumatoid arthritis using a humanized anti-interleukin 6 receptor antibody. Rheumatology (Oxford) 50: 1928-1930, 2011
47. Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K, Fleisher T, Balow JE, Lipsky PE: Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum 62: 542-552, 2010
48. Okazaki M, Yamada Y, Nishimoto N, Yoshizaki K, Mihara M: Characterization of anti-mouse interleukin-6 receptor antibody. Immunol Lett 84: 231-240, 2002
49. McFarland-ManciniMM, FunkHM, PaluchAM,ZhouM,Giridhar PV,Mercer CA, Kozma SC, Drew AF: Differences in wound healing in mice with deficiency of IL-6 versus IL-6 receptor. J Immunol 184: 7219-7228, 2010
50. Kitching AR, Holdsworth SR: The emergence of TH17 cells as effectors of renal injury. J Am Soc Nephrol 22: 235-238, 2011
51. Marks BR,NowyhedHN,Choi JY, Poholek AC,Odegard JM, Flavell RA, Craft J: Thymic self-reactivity selects natural interleukin 17-producing T cells that can regulate peripheral inflammation. Nat Immunol 10: 1125-1132, 2009
52. Tanaka S, Yoshimoto T, Naka T, Nakae S, Iwakura Y, Cua D, Kubo M: Natural occurring IL-17 producing T cells regulate the initial phase of neutrophilmediated airway responses. J Immunol 183: 7523-7530, 2009
53. Kimura A, Naka T, Kishimoto T: IL-6-dependent and-independent pathways in the development of interleukin 17-producing T helper cells. Proc Natl Acad Sci U S A 104: 12099-12104, 2007
54. Waetzig GH, Rose-John S: Hitting a complex target: An update on interleukin-6 trans-signalling. Expert Opin Ther Targets 16: 225-236, 2012
55. Waiser J, Budde K, Katalinic A, Kuerzdörfer M, Riess R, Neumayer HH: Interleukin-6 expression after renal transplantation. Nephrol Dial Transplant 12: 753-759, 1997
56. Taga T: The signal transducer gp130 is shared by interleukin-6 family of haematopoietic and neurotrophic cytokines. AnnMed 29: 63-72, 1997
57. Cochrane CG, Unanue ER, Dixon FJ: A role of polymorphonuclear leukocytes and complement in nephrotoxic nephritis. J Exp Med 122: 99-116, 1965
58. Anders HJ, Ryu M: Renal microenvironments and macrophage phenotypes determine progression or resolution of renal inflammation and fibrosis. Kidney Int 80: 915-925, 2011
59. Mauer J, Chaurasia B, Goldau J, Vogt MC, Ruud J, Nguyen KD, Theurich S, Hausen AC, Schmitz J, Brönneke HS, Estevez E, Allen TL, Mesaros A, Partridge L, Febbraio MA, Chawla A, Wunderlich FT, Brüning JC: Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-associated resistance to insulin. Nat Immunol 15: 423-430, 2014
60. Kluger MA, Luig M, Wegscheid C, Goerke B, Paust HJ, Brix SR, Yan I, Mittrücker HW, Hagl B, Renner ED, Tiegs G, Wiech T, Stahl RA, Panzer U, Steinmetz OM: Stat3 programs Th17-specific regulatory T cells to control GN. J Am Soc Nephrol 25: 1291-1302, 2014
61. Hoge J, Yan I, Jänner N, Schumacher V, Chalaris A, Steinmetz OM, Engel DR, Scheller J, Rose-John S, Mittrücker HW: IL-6 controls the innate immune response against Listeria monocytogenes via classical IL-6 signaling. J Immunol 190: 703-711, 2013
62. Kluger MA, Zahner G, Paust HJ, Schaper M, Magnus T, Panzer U, Stahl RA: Leukocyte-derived MMP9 is crucial for the recruitment of proinflammatory macrophages in experimental glomerulonephritis. Kidney Int 83: 865-877, 2013